 SHANGHAI and HONG KONG, April 5, 2021 PRNewswire -- Antengene Corporation Limited Antengene, SEHK: 6996.HK, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class andor best-in class therapeutics in hematology and oncology, today announced that the National Medical Products Administration NMPA has approved the Investigational New Drug IND application for a Phase I clinical trial to evaluate safety and toler ability of ATG-019 monotherapy or combined with niacin ER in patients with advanced solid tumors or non-Hodgkins lymphoma NHL in China. As an orally bioavailable dual PAK4NAMPT inhibitor, ATG-019 can lead to antitumor effects through energy depletion, inhibition of DNA repair, cell cycle arrest, inhibition of proliferation, and ultimately cell apoptosis. 